X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2578) 2578
Publication (453) 453
Book Review (9) 9
Book Chapter (2) 2
Dissertation (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Presentation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2070) 2070
index medicus (1935) 1935
niacinamide - analogs & derivatives (1610) 1610
male (1281) 1281
female (1048) 1048
animals (998) 998
oncology (956) 956
sorafenib (924) 924
middle aged (777) 777
phenylurea compounds (773) 773
phenylurea compounds - pharmacology (771) 771
cancer (721) 721
antineoplastic agents - therapeutic use (690) 690
aged (663) 663
phenylurea compounds - therapeutic use (663) 663
adult (523) 523
treatment outcome (491) 491
mice (488) 488
phenylurea compounds - administration & dosage (459) 459
pyridines - therapeutic use (459) 459
liver neoplasms - drug therapy (441) 441
carcinoma, hepatocellular - drug therapy (440) 440
niacinamide - therapeutic use (436) 436
pharmacology & pharmacy (411) 411
antineoplastic agents (393) 393
antimitotic agents (377) 377
benzenesulfonates - therapeutic use (377) 377
care and treatment (377) 377
cell line, tumor (369) 369
angiogenesis (366) 366
phenylurea compounds - adverse effects (347) 347
protein kinase inhibitors - therapeutic use (339) 339
hepatocellular carcinoma (335) 335
antineoplastic agents - adverse effects (329) 329
antineoplastic agents - pharmacology (315) 315
niacinamide - administration & dosage (310) 310
rats (293) 293
analysis (283) 283
carcinoma, renal cell - drug therapy (276) 276
liver neoplasms - pathology (276) 276
kidney neoplasms - drug therapy (272) 272
aged, 80 and over (269) 269
therapy (269) 269
chemotherapy (264) 264
carcinoma, hepatocellular - pathology (262) 262
expression (262) 262
research (261) 261
medicine & public health (258) 258
niacinamide - pharmacology (256) 256
liver cancer (254) 254
pyridines - adverse effects (252) 252
tumors (251) 251
protein kinase inhibitors - pharmacology (246) 246
antineoplastic agents - administration & dosage (243) 243
endothelial growth-factor (241) 241
article (239) 239
metastasis (237) 237
cell proliferation - drug effects (236) 236
apoptosis (235) 235
bevacizumab (230) 230
vascular endothelial growth factor (228) 228
pyridines - pharmacology (227) 227
sunitinib (224) 224
survival (221) 221
disease-free survival (220) 220
hepatoma (217) 217
antineoplastic combined chemotherapy protocols - therapeutic use (216) 216
pyridines - administration & dosage (215) 215
dose-response relationship, drug (214) 214
niacinamide - adverse effects (212) 212
hematology (208) 208
drug therapy (204) 204
apoptosis - drug effects (202) 202
benzenesulfonates - adverse effects (198) 198
prognosis (195) 195
neoplasms (186) 186
gastroenterology & hepatology (185) 185
phenylurea compounds - pharmacokinetics (183) 183
protein kinase inhibitors - adverse effects (183) 183
digestive system diseases (180) 180
retrospective studies (179) 179
benzenesulfonates - administration & dosage (177) 177
benzenesulfonates - pharmacology (163) 163
indoles - therapeutic use (161) 161
neoplasms - drug therapy (161) 161
antitumor-activity (159) 159
pyrroles - therapeutic use (159) 159
kinases (158) 158
xenograft model antitumor assays (158) 158
time factors (157) 157
renal-cell carcinoma (155) 155
health aspects (154) 154
signal transduction - drug effects (152) 152
clinical trials (151) 151
cell biology (148) 148
protein kinase inhibitors - administration & dosage (147) 147
cancer therapies (146) 146
tyrosine kinase inhibitor (145) 145
disease models, animal (142) 142
efficacy (141) 141
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2534) 2534
Japanese (13) 13
French (9) 9
German (7) 7
Chinese (6) 6
Hungarian (5) 5
Russian (5) 5
Bulgarian (2) 2
Italian (1) 1
Slovak (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 2, pp. 157 - 157
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2016, Volume 22, Issue 10, pp. 2368 - 2376
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 05/2014, Volume 466, Issue 1-2, pp. 172 - 180
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 195 - 206
To evaluate the mass balance, metabolic disposition, and pharmacokinetics of a single dose of regorafenib in healthy volunteers. In addition, in vitro... 
Human | Regorafenib | Phase I | Medicine & Public Health | Biotransformation | Oncology | Cancer Research | Pharmacology/Toxicology | Metabolism | MULTICENTER | EFFICACY | SAFETY | BAY 73-4506 | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | COLORECTAL-CANCER | IMATINIB | PHASE-3 TRIAL | DOUBLE-BLIND | SUNITINIB | PHARMACOLOGY & PHARMACY | Chromatography, High Pressure Liquid - methods | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - administration & dosage | Hepatocytes - metabolism | Healthy Volunteers | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Scintillation Counting | Tandem Mass Spectrometry - methods | Pyridines - administration & dosage | Administration, Oral | Liver - metabolism | Phenylurea Compounds - blood | Urinalysis - methods | Pyridines - blood | Feces - chemistry | Phenylurea Compounds - administration & dosage | Antineoplastic Agents - blood | Metabolites | Analysis | Pyridine | Urine | Plasma | Pyridines | Excretion | Oxidative metabolism | Risk reduction | Pharmacology | Liquid chromatography | High-performance liquid chromatography | Hepatocytes | Scintillation counters | Collection | Feces | Pharmacokinetics | Drug dosages | Radioactivity | Original
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 955 - 968
LY2603618 is an inhibitor of checkpoint kinase 1 (CHK1), an important regulator of the DNA damage checkpoints. Preclinical experiments analyzed NCI-H2122 and... 
Medicine & Public Health | CHK1 | Lung cancer | Cell cycle | Oncology | LY2603618 | Pharmacology/Toxicology | Pharmacokinetics | Cancer | PLUS CISPLATIN | DNA-DAMAGE | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | FLUOROURACIL | GEMCITABINE | CELL LUNG-CANCER | CHECKPOINT KINASE-1 | ONCOLOGY | ABROGATION | PHARMACOLOGY & PHARMACY | Cisplatin - pharmacokinetics | Glutamates - adverse effects | Antineoplastic Combined Chemotherapy Protocols - blood | Guanine - analogs & derivatives | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Neoplasms - blood | Phenylurea Compounds - adverse effects | Adult | Cisplatin - blood | Female | Glutamates - blood | Guanine - adverse effects | Phenylurea Compounds - pharmacokinetics | Guanine - pharmacokinetics | Glutamates - pharmacokinetics | Phenylurea Compounds - blood | DNA - metabolism | Pemetrexed | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Guanine - blood | Animals | Phenylurea Compounds - administration & dosage | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Cell Line, Tumor | Cisplatin - adverse effects | Glutamates - administration & dosage | Aged | Neoplasms - pathology | Pyrazines - blood | Guanine - administration & dosage | Complications and side effects | DNA damage | Development and progression | Research | Risk factors | Studies | Pharmacology | Inhibitor drugs | Cancer therapies | Analysis | Reaction kinetics | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2014, Volume 32, Issue 1, pp. 104 - 112
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 02/2014, Volume 53, Issue 2, pp. 185 - 196
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 01/2015, Volume 32, Issue 7, pp. 2205 - 2216
Purpose: Regorafenib is a novel multikinase inhibitor, currently approved for the treatment of metastasized colorectal cancer and advanced gastrointestinal... 
brain accumulation | Biotechnology | ABCB1 | testis accumulation | Pharmaceutical Science | Pharmacology (medical) | Molecular Medicine | Pharmacology | regorafenib | ABCG2 | Organic Chemistry | Biochemistry, general | Biomedical Engineering | Biomedicine | Pharmacy | Medical Law | Pharmacology/Toxicology | MULTICENTER | TRANSPORTER | BARRIER | PENETRATION | SORAFENIB | CHEMISTRY, MULTIDISCIPLINARY | PHARMACOKINETICS | SUNITINIB | PHARMACOLOGY & PHARMACY | INHIBITOR | Testis - metabolism | Humans | Pyridines - pharmacokinetics | Male | Neoplasm Proteins - metabolism | Antineoplastic Agents - metabolism | Brain - metabolism | Tissue Distribution | Transfection | ATP-Binding Cassette Transporters - genetics | Biological Transport | Madin Darby Canine Kidney Cells | ATP-Binding Cassette Transporters - metabolism | ATP Binding Cassette Transporter, Subfamily B - genetics | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - metabolism | Phenylurea Compounds - pharmacokinetics | Neoplasm Proteins - genetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | Administration, Oral | Phenylurea Compounds - blood | ATP Binding Cassette Transporter, Subfamily B - metabolism | Mice, Knockout | Pyridines - blood | Animals | Pyridines - metabolism | Dogs | Antineoplastic Agents - blood | Mice | Brain | Breast cancer | Metabolites | Colorectal cancer | Inhibitor drugs | Kinases | Rodents | Pharmaceutical sciences
Journal Article
Molecules, ISSN 1420-3049, 07/2017, Volume 22, Issue 7, p. 1034
Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). In Asia, patients with HCC are potentially treated with the... 
Chinese herbal medicine | Hepatocellular carcinoma | Pharmacokinetics | Radix Gentianae formulation | Sorafenib | sorafenib | BIOCHEMISTRY & MOLECULAR BIOLOGY | ALTERNATIVE MEDICINE | INGREDIENTS | CHEMISTRY, MULTIDISCIPLINARY | HEPATOCELLULAR-CARCINOMA | INHIBITION | INTRAUTERINE INFECTION | CIRRHOSIS | LIVER | pharmacokinetics | HEPATITIS-B | hepatocellular carcinoma | Niacinamide - analogs & derivatives | Liver - pathology | Niacinamide - blood | Drugs, Chinese Herbal - pharmacology | Rats | Male | Phenylurea Compounds - blood | Medicine, Chinese Traditional - methods | Phenylurea Compounds - toxicity | Rats, Sprague-Dawley | Dose-Response Relationship, Drug | Drugs, Chinese Herbal - pharmacokinetics | Animals | Liver - drug effects | Herb-Drug Interactions | Antineoplastic Agents - blood | Niacinamide - pharmacokinetics | Niacinamide - toxicity | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phenylurea Compounds - pharmacokinetics | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Herbs | Cytochrome | Ketoconazole | Liver | Cytochrome P450 | Drug interactions | Oral administration | Pharmacology | Liquid chromatography | Metabolism | Photodiodes | High-performance liquid chromatography | Herbal medicine | Medicine | Side effects | Histopathology | Grapefruit | Drug interaction | Pretreatment | Hepatotoxicity | Cytochromes P450
Journal Article
Journal Article
Thyroid : official journal of the American Thyroid Association, ISSN 1050-7256, 09/2017, Volume 27, Issue 9, pp. 1118 - 1127
Journal Article